<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="804">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936649</url>
  </required_header>
  <id_info>
    <org_study_id>GE-122-015</org_study_id>
    <nct_id>NCT01936649</nct_id>
  </id_info>
  <brief_title>Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.</brief_title>
  <official_title>A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView (Iobenguane I 123 Injection)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H2O Clinical LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the reproducibility of quantitative measurements of
      myocardial uptake of Iobenguane I 123 on planar and SPECT imaging following intravenous
      (iv.) administration of AdreView. Efficacy will be assessed based upon the absolute
      differences between quantitative analyses of imaging data on 2 scans performed 5 to 14 days
      apart.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Test-retest Reproducibility on Measurements of Heart/Mediastinum (H/M) Ratio and the Extent of the Difference Between H/M Measurements Following AdreView and 3 Hour 50 Minute Delayed Planar Imaging on 2 Separate Days Within an Interval of 5 to 14 Days.</measure>
    <time_frame>Two separate AdreView™ SPECT scintigraphy imaging days within an interval of 5 to 14 days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The summary statistics for the results from the two 3-hour 50-minute delayed planar imaging sessions for each subject and the absolute difference between the test and retest Heart/Mediastinum (H/M) ratios.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test-retest Reproducibility on Measurements of Heart/Mediastinum (H/M) Ratio and Extent of the Difference Between H/M Measurements Following AdreView Use and 15 Minute Delayed Planar Imaging on 2 Separate Days Within an Interval of 5 to 14 Days.</measure>
    <time_frame>Two separate AdreView SPECT scintigraphy imaging days within an interval of 5 to 14 days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The summary statistics for the results from the two 15-minute delayed planar imaging sessions for each subject and the absolute difference between the test and retest Heart/Mediastinum (H/M) ratios.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Heart Failure (HF)</condition>
  <condition>Ventricular Dysfunction, Left</condition>
  <arm_group>
    <arm_group_label>AdreView Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AdreView given at 10 millicuries (mCi) as a single iv. administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AdreView</intervention_name>
    <description>AdreView 10 millicuries (mCi) as a single iv. administration</description>
    <arm_group_label>AdreView Arm 1</arm_group_label>
    <other_name>I-123 Iobenguane injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject was originally diagnosed with NYHA Class II-III HF due to ischemic heart
             disease at least 3 months or due to non-ischemic cardiomyopathy at least 6 months
             before enrolment into the study.

          -  The subject has Left Ventricular (LV) dysfunction with Left Ventricular Ejection
             Fraction (LVEF) less than or equal to 35% measured by an appropriate method (e.g.,
             radionuclide or contrast ventriculography, electrocardiogram (ECG)-gated SPECT
             myocardial perfusion imaging [MPI], magnetic resonance imaging, CT or
             echocardiography) within 6 months of enrolment into the study and documented in the
             subject's medical record.

          -  The subject has a history of compliance with prescribed HF medications and takes
             Heart Failure (HF) guidelines-based medication at study entry including at a minimum
             a beta-blocker and either an angiotensin converting enzyme inhibitor or angiotensin
             receptor antagonist unless documented to be intolerant to any of these classes of
             medications.

          -  The subject has been on a stable medical regimen for a minimum of 3 months, with no
             hospitalizations or change in HF medications or HF symptoms.

          -  Subjects must be clinically stable for at least 7 days before enrolling in the study
             (e.g., not experiencing continuing chest pain or hemodynamic instability).

        Exclusion Criteria:

          -  The subject has previously received 123I-mIBG or 131I-mIBG.

          -  The subject has known or suspected hypersensitivity/allergy to iodine, Iobenguane or
             to any of the excipients in AdreView.

          -  The subject has had a heart transplant at any time prior to enrollment.

          -  The subject had LVEF greater than 35% as measured by an appropriate method (e.g.,
             radionuclide or contrast ventriculography, ECG-gated SPECT MPI, MR, CT, or
             echocardiography) within 30 days prior to enrolment into the study.

          -  The subject has received defibrillation (either external or via an implantable
             cardioverter defibrillator [ICD]), anti-tachycardia pacing, or cardioversion to treat
             an arrhythmic event in the previous 90 days.

          -  The subject had a cardiac revascularization, insertion of an ICD, or acute myocardial
             infarction within 30 days before study entry.

          -  The subject has renal insufficiency (creatinine greater than 3 mg/dl).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold Jacobson, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 9, 2015</lastchanged_date>
  <firstreceived_date>September 3, 2013</firstreceived_date>
  <firstreceived_results_date>January 14, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nuclear imaging</keyword>
  <keyword>Radiopharmaceutical</keyword>
  <keyword>Iobenguane</keyword>
  <keyword>I-123</keyword>
  <keyword>reproducibility</keyword>
  <keyword>Quantitative measurements</keyword>
  <keyword>myocardial uptake</keyword>
  <keyword>SPECT imaging</keyword>
  <keyword>planar imaging</keyword>
  <keyword>AdreView™</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>51 Subjects completed safety assessment. 47 subjects completed the efficacy analysis.</recruitment_details>
      <pre_assignment_details>63 Subjects enrolled in the study. 50 Subjects completed this study. 51 Subjects completed safety assessment. 47 subjects completed the efficacy analysis. 13 Subjects discontinued in this study. 12 Subjects discontinued prior to contrast administration (No contrast received).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AdreView Arm 1</title>
          <description>AdreView: AdreView 10 millicuries (mCi) as a single iv. administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Safety Assessment</title>
              <participants_list>
                <participants group_id="P1" count="51">51 subjects went through the safety assessment of this study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Efficacy Analysis</title>
              <participants_list>
                <participants group_id="P1" count="47">47 subjects completed the efficacy analysis portion of this study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50">Completed this study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failures</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>63 Subjects enrolled in the study. 50 Subjects completed this study. 51 Subjects completed safety assessment. 47 subjects completed the efficacy analysis. 13 Subjects discontinued in this study. 12 Subjects discontinued prior to contrast administration (No contrast received).</population>
      <group_list>
        <group group_id="B1">
          <title>AdreView Arm 1</title>
          <description>AdreView: AdreView 10 millicuries (mCi) as a single iv. administration</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65.2" spread="12.46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Safety Assessment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Test-retest Reproducibility on Measurements of Heart/Mediastinum (H/M) Ratio and the Extent of the Difference Between H/M Measurements Following AdreView and 3 Hour 50 Minute Delayed Planar Imaging on 2 Separate Days Within an Interval of 5 to 14 Days.</title>
        <description>The summary statistics for the results from the two 3-hour 50-minute delayed planar imaging sessions for each subject and the absolute difference between the test and retest Heart/Mediastinum (H/M) ratios.</description>
        <time_frame>Two separate AdreView™ SPECT scintigraphy imaging days within an interval of 5 to 14 days.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Summary of Heart/Mediastinum (H/M) Ratio Results and Absolute Differences for the Test and Retest 3-Hours and 50 Minutes from Planar AdreView Images. Average of 3 technologists is calculated based on non-missing technologists reviewing results. All non-missing technologist evaluations were averaged per subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Technologist A</title>
          </group>
          <group group_id="O2">
            <title>Technologist B</title>
          </group>
          <group group_id="O3">
            <title>Technologist C</title>
          </group>
          <group group_id="O4">
            <title>Average of 3 Technologists</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Test-retest Reproducibility on Measurements of Heart/Mediastinum (H/M) Ratio and the Extent of the Difference Between H/M Measurements Following AdreView and 3 Hour 50 Minute Delayed Planar Imaging on 2 Separate Days Within an Interval of 5 to 14 Days.</title>
            <description>The summary statistics for the results from the two 3-hour 50-minute delayed planar imaging sessions for each subject and the absolute difference between the test and retest Heart/Mediastinum (H/M) ratios.</description>
            <units>Summary of H/M Ratio Results</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Post-Dosing Number 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.435" lower_limit="1.368" upper_limit="1.501"/>
                  <measurement group_id="O2" value="1.430" lower_limit="1.364" upper_limit="1.495"/>
                  <measurement group_id="O3" value="1.427" lower_limit="1.365" upper_limit="1.489"/>
                  <measurement group_id="O4" value="1.429" lower_limit="1.365" upper_limit="1.492"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Dosing Number 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.422" lower_limit="1.356" upper_limit="1.487"/>
                  <measurement group_id="O2" value="1.436" lower_limit="1.375" upper_limit="1.497"/>
                  <measurement group_id="O3" value="1.441" lower_limit="1.384" upper_limit="1.498"/>
                  <measurement group_id="O4" value="1.433" lower_limit="1.373" upper_limit="1.493"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Absolute Difference between Dose 1 and 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.070" lower_limit="0.052" upper_limit="0.088"/>
                  <measurement group_id="O2" value="0.060" lower_limit="0.048" upper_limit="0.072"/>
                  <measurement group_id="O3" value="0.067" lower_limit="0.051" upper_limit="0.083"/>
                  <measurement group_id="O4" value="0.065" lower_limit="0.055" upper_limit="0.076"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Test-retest Reproducibility on Measurements of Heart/Mediastinum (H/M) Ratio and Extent of the Difference Between H/M Measurements Following AdreView Use and 15 Minute Delayed Planar Imaging on 2 Separate Days Within an Interval of 5 to 14 Days.</title>
        <description>The summary statistics for the results from the two 15-minute delayed planar imaging sessions for each subject and the absolute difference between the test and retest Heart/Mediastinum (H/M) ratios.</description>
        <time_frame>Two separate AdreView SPECT scintigraphy imaging days within an interval of 5 to 14 days.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Summary statistics for Absolute Difference in H/M Ratios for the Two 15-Minute Planar AdreView Images. Average of 3 technologists is calculated based on non-missing technologists reviewing results. All non-missing technologist evaluations were averaged per subject. These results were then summarized overall for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Technologist A</title>
          </group>
          <group group_id="O2">
            <title>Technologist B</title>
          </group>
          <group group_id="O3">
            <title>Technologist C</title>
          </group>
          <group group_id="O4">
            <title>Average of 3 Technologists</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="47"/>
                  <measurement group_id="O4" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Test-retest Reproducibility on Measurements of Heart/Mediastinum (H/M) Ratio and Extent of the Difference Between H/M Measurements Following AdreView Use and 15 Minute Delayed Planar Imaging on 2 Separate Days Within an Interval of 5 to 14 Days.</title>
            <description>The summary statistics for the results from the two 15-minute delayed planar imaging sessions for each subject and the absolute difference between the test and retest Heart/Mediastinum (H/M) ratios.</description>
            <units>Summary of H/M Ratio Results</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Post-Dosing Number 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.584" lower_limit="1.518" upper_limit="1.650"/>
                  <measurement group_id="O2" value="1.568" lower_limit="1.501" upper_limit="1.634"/>
                  <measurement group_id="O3" value="1.593" lower_limit="1.527" upper_limit="1.658"/>
                  <measurement group_id="O4" value="1.581" lower_limit="1.517" upper_limit="1.646"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Post-Dosing Number 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.567" lower_limit="1.500" upper_limit="1.633"/>
                  <measurement group_id="O2" value="1.553" lower_limit="1.490" upper_limit="1.617"/>
                  <measurement group_id="O3" value="1.571" lower_limit="1.506" upper_limit="1.636"/>
                  <measurement group_id="O4" value="1.564" lower_limit="1.499" upper_limit="1.628"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Absolute difference between dose 1 and 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.081" lower_limit="0.059" upper_limit="0.104"/>
                  <measurement group_id="O2" value="0.062" lower_limit="0.047" upper_limit="0.078"/>
                  <measurement group_id="O3" value="0.071" lower_limit="0.055" upper_limit="0.087"/>
                  <measurement group_id="O4" value="0.072" lower_limit="0.057" upper_limit="0.086"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AdreView Arm 1</title>
          <description>AdreView given at 10 millicuries (mCi) as a single iv. administration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jose Zubeldia</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>011-44-1494-543137</phone>
      <email>jose.zubeldia@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
